Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
An IL-6 neutralization antibody (or IL-6 neutralizing antibody) is a class of monoclonal antibodies designed to bind directly to interleukin-6 (IL-6) and neutralize its biological activity. IL-6 is a pleiotropic pro-inflammatory cytokine that plays a pivotal role in immune regulation, hematopoiesis, and inflammation. By binding to IL-6, these antibodies prevent it from interacting with the membrane-bound or soluble IL-6 receptor (IL-6R), thereby blocking the assembly of the IL-6/IL-6R/gp130 signaling complex and inhibiting downstream JAK/STAT and MAPK signaling pathways. This therapeutic approach is widely utilized to treat chronic inflammatory and autoimmune diseases, such as rheumatoid arthritis, multicentric Castleman disease, and cytokine release syndrome (CRS).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IL-6 neutralization antibody.